Stu Needleman, Chief Commercial Officer at Piramal Pharma Solutions, discusses the Biosecure Act and other big trends shaking up the industry, including GLP-1s, consolidation in the CDMO sector, and sterile fill-finish. He tells us more about Piramal’s $80-million expansion in Kentucky and how the company is adapting to the changes in the market. Check out the video!
Recommended
Related Content
Choosing a Sterile Fill-Finish Partner
October 22, 2026
5 min read
Alcami’s Kerrie Powell, Senior VP of Sales, discusses the challenges of sterile biologics manufacturing and what sponsors should look for in a CDMO partner
Video: Sitting Down With… John Tomtishen
October 7, 2026
1 min read
Catalent’s John Tomtishen discusses his path into cell therapy and the evolving approaches to CMC, manufacturing, and commercialization
Video: From Accounting to Action on Pharma Sustainability
October 2, 2026
1 min read
Ahead of CPHI Milan’s Sustainability Summit, Silvia Forroova and Rob Williams discuss how shared standards and supplier partnerships can turn commitments into measurable progress.
The Resilience Prescription
October 2, 2026
5 min read
We asked the 2026 Power List how the pharmaceutical industry can prepare for geopolitical, economic, regulatory, and scientific uncertainty
